Clearing the way
Panelists reflect on exciting dermatologic discoveries and upcoming advancement opportunities.
P001 – Pipeline Therapies in Dermatology
10 a.m.–noon | Friday, July 11
Grand Ballroom D
Dermatology is keeping its finger on the pulse of the research pipeline, tracking the potential for key discoveries that will make a difference while staying steadfast in the quest to keep it primed for the future.
Exploring that pipeline is the focus of the 2025 AAD Innovation Academy session, P001 – Pipeline Therapies in Dermatology. According to session director Neal D. Bhatia, MD, FAAD, speakers will segment the conversation into topicals, systemics, biologics, and devices.
“We’ll have panelists talking about what’s new in the pipeline, including research and early phase 1 and 2 trials. Then we’ll have the counterpoint of what’s already available and what’s about to be released,” said Dr. Bhatia, director of clinical dermatology at Therapeutics Clinical Research in San Diego.
Neal D. Bhatia, MD, FAAD
“It all stems from the departure of medical dermatology and how dermatologists are giving away medical dermatology. The result of that is less funding for new topical agents,” Dr. Bhatia said. “Sponsors are seeing the writing on the wall that these drugs aren’t going to get covered or supported, and relying on inefficient, generic drugs will lead to bad outcomes for patients. Dermatologists must fight for these new drugs and be advocates for pipeline research and potential novel mechanisms.”
In addition to identifying and categorizing new and potential therapeutic advances in early- to late-phase clinical research trials, panelists will discuss and evaluate the gaps, opportunities, and shifting treatment types that could affect the dermatology landscape.
The full panel of speakers includes Leon H. Kircik, MD, FAAD; Edward L. Lain, MD, FAAD; George Michael Lewitt, MD, FAAD; Andrea Tesvich Murina, MD, FAAD; Todd Schlesinger, MD, FAAD; Raja Sivamani, MD, FAAD; and Jonathan S. Weiss, MD, FAAD.
